Stock of Cytokinetics, Incorporated (CYTK) is rising about 17 percent in Tuesday morning trading after the company announced positive topline results from ACACIA-HCM, its pivotal Phase 3 clinical trial evaluating Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.
The company's shares are currently trading at $77.79 on the Nasdaq, up 17.72 percent. The stock opened at $74.52 and has moved as high as $77.46 so far in today's session. Over the past year, it has traded in a range of $29.31 to $77.46.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.